[Update on Li-Fraumeni syndrome]

Area of Science:

• Oncology
• Genetics
• Cancer Predisposition Syndromes

Background:

• Li-Fraumeni syndrome (LFS) is an aggressive inherited cancer predisposition syndrome.
• It is characterized by a high risk of various cancers, including sarcomas, brain tumors, breast cancer, and adrenocortical carcinoma, often developing at a young age.
• LFS follows an autosomal dominant inheritance pattern with variable penetrance.

Purpose of the Study:

• To highlight the aggressive nature and genetic basis of Li-Fraumeni syndrome.
• To emphasize the need for structured early detection and surveillance strategies for LFS patients.
• To introduce the LFS cancer predisposition registry for patient data collection and research.

Main Methods:

• Review of existing literature on Li-Fraumeni syndrome.
• Molecular genetic analysis identifying germline mutations in the TP53 gene.
• Establishment of a dedicated LFS cancer predisposition registry.

Main Results:

• LFS is caused by germline mutations in the TP53 gene, leading to a loss of functional p53 protein.
• This loss impairs cellular antitumor responses, significantly increasing cancer risk.
• The prevalence of LFS is approximately 1:5000, with considerable interregional variation.

Conclusions:

• Early recognition and surveillance strategies are essential to improve survival in individuals with Li-Fraumeni syndrome.
• Further longitudinal observational studies are needed to assess the cost-effectiveness of surveillance.
• The LFS cancer predisposition registry aims to facilitate research and improve patient management.